Sky and Bradford Facilities Combine for Over
128,000 kg per Year Production Capacity
TSX | NYSE: ACB
EDMONTON, Feb. 25, 2019
/CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE:
ACB) (TSX: ACB) (Frankfurt: 21P;
WKN: A1C4WM) today announced that both its Aurora Sky and MedReleaf
Bradford facilities are now fully licensed by Health Canada for the
production and sale of cannabis and cannabis derivative
products.
"The rapid scale-up of our production capacity - with our Sky
and Bradford facilities specifically adding over 128,000 kg per
year in capacity - is resulting in significant increases in product
availability across our domestic medical and consumer, as well as
our international market segments, over the coming months," said
Terry Booth, CEO of Aurora. "Current
production at Aurora Sky, with recent harvests exceeding target
yields, validates our production philosophy and our investment in
high-tech, highly automated facilities. MedReleaf Bradford employs
best practices identified during the integration of the Aurora and
MedReleaf organizations, and is consistently delivering exceptional
yields and high-quality product that has resonated well in both the
medical and consumer markets."
Aurora Sky
Located at the Edmonton
International Airport in Alberta,
Aurora Sky is the Company's first "Sky Class" facility. Aurora Sky
is designed to deliver high quality, consistent and highly
cost-efficient cannabis cultivation. At 800,000 square foot, the
facility delivers massive scale, incorporates state-of-the-art
technology, and leverages a high degree of automation to deliver
target production costs of well below one
dollar per gram. With the entire facility's cultivation
space now licensed by Health Canada, the Company anticipates the
facility to be fully planted in March
2019, with the full impact of product available for sale to
be realized by the end of June
2019.
MedReleaf Bradford
Located in Ontario, MedReleaf
Bradford is a 210,000 square foot high-tech production facility
built to EU GMP specifications which features 17 independently
climate-controlled grow rooms. Designed for large scale,
hang-dried, hand-manicured production, 13 of the flower rooms are
currently in production to service the consumer and medical
markets. With the facility's cultivation space now completely
licensed, Aurora anticipates the facility to be fully planted by
early April 2019, reflecting a
production capacity of 28,000 kg of high-quality cannabis per
annum.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 23 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland have achieved this level of
certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela,
and ICC Labs – Aurora is distinguished by its reputation as a
partner and employer of choice in the global cannabis sector,
having invested in and established strategic partnerships with a
range of leading innovators, including: Radient Technologies Inc.
(TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group
Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty
Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Neither the TSX, NYSE
nor their Regulation Services Provider (as that term is defined in
the policies of the TSX and NYSE) accepts responsibility for the
adequacy or accuracy of this release.
Terry Booth, CEO
Aurora Cannabis Inc.
Forward-Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and include, but are not limited to the cost
per gram of cannabis production, the capacity of production per
year, and the time frame for the facilities to be fully planted.
These statements are only predictions. Various assumptions were
used in drawing the conclusions or making the projections contained
in the forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-receives-health-canada-licensing-of-aurora-sky-and-medreleaf-bradford-300801050.html
SOURCE Aurora Cannabis Inc.